UniQure: How QURE Stock Rises 10x To $500?

1. QURE's AMT-130 shows a 75% reduction in Huntington's disease progression. 2. Potential annual revenue of $2-4 billion if approved and market penetrates 60%. 3. Tripling stock price reflects validation of a high-potential asset ahead of commercialization. 4. Risks include regulatory hurdles and challenges in scaling specialized manufacturing. 5. Additional pipeline developments could further diversify revenue beyond AMT-130.